Penn Medicine Abramson Cancer Center

 

Updates in Melanoma: Treatment, Clinical Trials and Coexisting with COVID-19
08:11

Penn Medicine Abramson Cancer Center

2021 Penn Medicine Update on Neoadjuvant Melanoma: How Can We Improve Outcomes in Patients With the Poor pR? What Are the Benefits of Neoadjuvant Therapy?

FEATURING Tara Mitchell
  • 110 views
  • March 5, 2021
  • 1
11:54

Penn Medicine Abramson Cancer Center

Expert Discussion on Melanoma Management: What Are the Complications from SLNB and the Role of Gene Expression Profiling? Are Biomarkers Important to Determine Neoadjuvant Trials Enrolment?

FEATURING Christopher J. Miller, John Miura, Tara Mitchell, Justine Cohen, Lynn Schuchter
  • 172 views
  • March 4, 2021
  • 1
15:32

Penn Medicine Abramson Cancer Center

COVID-19 Vaccination Guidelines for Our Cancer Patients: What Are the Eligibility Requirements and Exclusion Criteria? What Is the Efficacy of the Vaccine on Active Therapy?

FEATURING Lynn Schuchter
  • 63 views
  • March 4, 2021
  • 1
13:02

Penn Medicine Abramson Cancer Center

2021 Penn Medicine Update on IO & Targeted Therapies for Metastatic Melanoma: What Are the Available Management Options? What Is the Efficacy of Novel Triplet Therapy?

FEATURING Justine Cohen
  • 180 views
  • March 4, 2021
  • 1
05:23

Penn Medicine Abramson Cancer Center

Adjuvant Therapy in Stage III Melanoma: What Is the Adjuvant vs. Neoadjuvant Therapy Approach? RFS Efficacy of Dabrafenib/Trametinib, Nivo & Pembro

FEATURING Tara Mitchell
  • 111 views
  • March 4, 2021
12:00

Penn Medicine Abramson Cancer Center

2021 Update on SLNB for Localized Melanoma: Who Should Get the Procedure? Does CLND Improve Survival Among SLN+ Patients?

FEATURING John Miura
  • 273 views
  • March 4, 2021
  • 2
02:47

Penn Medicine Abramson Cancer Center

56 y/o Man With History of 7 Melanomas Presented With New AJCC T4a Melanoma: Does Neoadjuvant Pembro Reduce the Rate of Positive SLNB for Stage IIB/C Disease?

FEATURING Christopher J. Miller
  • 61 views
  • March 4, 2021